Roundtable: Focus on Multiple Myeloma
A collection of Roundtable discussions focused on important news and updates in multiple myeloma.
Advertisement
Advertisement
The panel talks about the future of CAR-T: more targets, sequencing, and other patient considerations.
The panel considers where CAR T-cell therapy should fit in the myeloma treatment paradigm.
The panel compares clinical trial and real-world data for CAR-Ts.
The panel discusses treatment-related side effects such as CRS, ICANS, and more.
Drs. Raje and Patel discuss how they decide between CAR-T and bispecifics for their myeloma patients.
The panel discusses which patients may not be suitable for CAR T-cell therapy.
The panel discussed how CAR-T impacts myeloma standard of care.
In the first segment of the roundtable series, the panel discussed the latest CAR-T data, including KarMMa-3 and CARTITUDE-4.
The panelists highlight key data presented at ASCO 2023.
Toxicities such as cytokine release syndrome as they relate to BCMA bispecific antibodies for myeloma are discussed.
The panel discusses the new and emerging bispecific antibody treatment options for multiple myeloma.
The panel discusses data on the BCMA CAR-T construct PHE885 and the manufacturing needs that persist.
The panel discusses the real-world data and first-hand experience with the two FDA-approved CAR T-cell therapies for MM.
The panelists discuss their experience with CAR-T access challenges in the real-world clinical setting.
The panel discusses the FDA-approved BCMA-directed CAR-T options for multiple myeloma.
The panel discusses maintenance therapy options for early-relapsed multiple myeloma.
The panel considers triplet versus quadruplet therapy for myeloma induction.
The panel advises on patient hand off to local care teams following CAR T-cell therapy for myeloma.
The panel discusses side effect management with CAR T-cell therapy.
The panel addresses the choice between treating multiple myeloma with a bispecific agent or CAR T-cell therapy.
Drs. Martin and Voorhees discuss patient characteristics and populations that are suited for CAR-T therapy in myeloma.
The panel addresses the potential for frontline CAR-T use.
The panel debates whether CAR-T can be moved earlier in the course of myeloma treatment.
The panel discusses allogeneic CAR T-cell therapy and how it stacks up against autologous options.
Drs. Lonial and Martin discuss allogeneic, off-the-shelf CAR-T data.
BCMA-targeted autologous CAR T-cell therapies are discussed.
The panel discusses the second FDA-approved CAR-T therapy for myeloma, ciltacabtagene autoleucel.
Drs. Voorhees and Martin discuss one of the FDA-approved CAR-T therapies for myeloma, idecabtagene vicleucel.
In the first segment of the roundtable series, the panel discusses BCMA as an important target for treating multiple myeloma.
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.